Applied DNA Sciences Q3 FY2024 revenue falls 72% YoY to $798K; operating loss widens

BNB PLUS CORP.

2024-Q3 EPS reported -$2.15 vs consensus -$260.10 ▲ beat (+99.2%)

Total revenues $798K for Q3 ended June 30, 2024, down from $2.9M, driven by end of CUNY COVID testing contract.
Gross profit $245K (31% margin) vs $1.3M (44%); operating loss $3.3M vs $2.9M year ago.
Adjusted EBITDA negative $3.2M vs negative $2.1M; cash position $10.4M up from $7.2M after $10.5M public offering.
LineaRx GMP facility on track for FY24 year-end launch; Linea IVT GMP runs expected early CY25.
Multi-year certainT agreement with Indus Group post-close; TR8 PGx testing capacity set at potential $25M annual revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.